“That's what we embedded in our guidance going forward. And that, you know, it could improve based on the appropriations dynamics this summer.”

In context

“iotech authorization. There's a lot of good things going on there. But we have seen very specific actions, and I suspect that others that do that particular activity in the short term will figure that out. I also believe that ultimately, as the policy people get in place, it's actually good medicine that's actually on some of those studies. So it's just a question of, you know, do they come back and if so, when? So that's how I think about that. It's kind of a one-off. In terms of the academic and government view, the balance of that, in terms of the phase in that machine, we don't guide by end market or that. The way I would just think about it is, you know, customers are putting in their mitigation actions. Would expect that US academic would be relatively soft, the balance of the year. That's what we embedded in our guidance going forward. And that, you know, it could improve based on the appropriations dynamics this summer. We haven't assumed that that creates a tailwind, but I would say we just affect put it in effect right throughout the balance of the year pretty much pro rata in terms of the impact. Rachel Vatnsdal: Great. And then for my follow-up, I just wanted to push on pricing assumptions. You called out just in light of tariffs that you can see some potential pricing offsets there. Can you walk us through your broad pricing assumptions, expectations for this year? How much do you really think you will be able to mitigate? How conservative are you being on those assumptions as well? And then what business days are you expecting more pricing and ability to pass that on through tariffs versus other areas where you maybe take less price in this environment? Marc Casper: Yeah. I think it's important to”